AMPE - Ampio Pharmaceuticals, Inc.
| Previous Close | 0.5000 |
| Open | 0.5080 |
| Bid | 0.5010 x 2900 |
| Ask | 0.5906 x 1800 |
| Day's Range | 0.5000 - 0.5172 |
| 52 Week Range | 0.3600 - 1.3100 |
| Volume | 532,164 |
| Avg. Volume | 959,360 |
| Market Cap | 75.051M |
| Beta (3Y Monthly) | 1.23 |
| PE Ratio (TTM) | 36.94 |
| EPS (TTM) | 0.0140 |
| Earnings Date | Nov 12, 2019 - Nov 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- PR Newswire
Ampio Retains Legal Counsel for Transaction Advisory Committee
ENGLEWOOD, Colo., Sept. 18, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) phase three clinical trial titled "Evaluating the Efficacy and Safety of Ampion to treat Adults with Pain Due to Severe Osteoarthritis of the Knee", today announced that Cooley LLP has been engaged to represent Ampio with respect to a potential strategic transaction, as well as related matters.
- PR Newswire
Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial
ENGLEWOOD, Colo. , Sept. 17, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) today announced the progress to date in the Company's special protocol assessment (SPA) phase three ...
- PR Newswire
Ampio Pharmaceuticals Retains Financial Advisor and Appoints Transaction Advisory Committee
ENGLEWOOD, Colo., Aug. 22, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a special protocol assessment (SPA) phase three clinical trial titled, "A Randomized, Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of an Intra-Articular Injection of Ampion™ in Adults with Pain Due to Severe Osteoarthritis of the Knee," today announced that the Company has retained Torreya Partners LLC as a financial advisor and has appointed Willam Bindley and Bruce E. Terker to a newly formed Transaction Advisory Committee (TAC).
- PR Newswire
Ampio Appoints Moss Adams LLP as the Company's New Independent Auditor
ENGLEWOOD, Colo., July 11, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common inflammatory conditions for which there are limited treatment options, today announced that its Audit Committee and Board of Directors appointed Moss Adams LLP as the Company's new independent auditor. Moss Adams has served for over 100 years as a fully integrated professional services firm with over 3,200 professionals across more than 25 locations in the western United States.
- PR Newswire
Ampio Appoints Dan Stokely as the Company's new Chief Financial Officer
ENGLEWOOD, Colo., July 10, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common inflammatory conditions for which there are limited treatment options, today announced that Dan Stokely has been appointed as Chief Financial Officer. Dan Stokely has more than 30 years of experience in finance and accounting and is a Certified Public Accountant.
- PR Newswire
Ampio Pharmaceuticals Announces Closing of $12 Million Public Offering
The Company intends to use the net proceeds from this offering for the full cost of its AP-013 clinical trial, titled "A Randomized, Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of an Intra-Articular Injection of Ampion in Adults with pain Due to Severe Osteoarthritis of the Knee," pursuant to its recently announced Special Protocol Assessment and for other general corporate purposes. The shares of common stock in this offering were offered on a reasonable best efforts, any and all basis pursuant to an effective shelf registration statement.
- PR Newswire
Ampio Pharmaceuticals Announces Pricing of Public Offering
The Company intends to use the net proceeds from this offering for the full cost of its AP-013 clinical trial pursuant to its recently announced Special Protocol Assessment and other general corporate purposes. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as the exclusive placement agent for this transaction.
- PR Newswire
Ampio Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
ENGLEWOOD, Colo., June 14, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) ("Ampio"), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Ampio expects to grant the underwriters a 45-day option to purchase additional shares of common stock offered in the public offering. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.
- PR Newswire
Ampio Regulatory and Clinical Update
According to Michael Macaluso, Ampio CEO, "The Company has identified and engaged 15 clinical sites for the trial (AP-013) and patient identification is underway. This pivotal trial seeks to enroll approximately 1,000 patients, with an interim look, to allow sample size adjustments, if required.
- PR Newswire
Ampio Clinical, Regulatory and Corporate Update
Clinical: The results of the AP-003-C open label extension study outlining the safety and efficacy of repeat injections of Ampion™ in patients with severe osteoarthritis-of-the-knee (OAK) have been accepted as a podium presentation at the 83rd Annual Meeting of the Western Orthopedic Association (WOA) in Monterey, CA., held from July 31st to August 3rd, 2019. The WOA meeting was developed primarily for orthopedic and trauma surgeons and allied health professionals. The WOA Committee selected multiple research papers and invited nationally respected speakers to present practice-related techniques and findings in orthopedic surgery that cover a variety of specialty orthopedic disciplines and advances in treatment. The Ampion study is entitled "Investigating Repeated Intra-Articular Injections of The Anti-Inflammatory Compound LMWF-5A (Ampion) In Adults with Severe Osteoarthritis: An Open-Label Extension Study" and will be presented by orthopedic surgeon, John Schwappach, MD.
- PR Newswire
Ampio Pharmaceuticals Provides Regulatory Update
ENGLEWOOD, Colo., April 29, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has received comments from the U.S. Food and Drug Administration (FDA) regarding their Special Protocol Assessment (SPA). The FDA recommended the Company not start their confirmatory trial without obtaining FDA concurrence on the trial design. The Company agreed with the comments they received from the FDA and immediately sent a revised SPA to the FDA for review.
- PR Newswire
Ampio Pharmaceuticals Provides Corporate Update
ENGLEWOOD, Colo., March 26, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that on March 11, 2019, the Company resubmitted a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA) for a confirmatory Phase III clinical trial of its biological drug, Ampion™, for the treatment of patients afflicted with Osteoarthritis of the Knee (OAK). Mr. Macaluso, Ampio's CEO added, "After a series of interactions with the FDA, we believe we have addressed and answered all questions regarding trial design. The FDA confirmed they would respond to our SPA submission no later than April 25, 2019.
- PR Newswire
Ampio Updates Regulatory Status for Ampion
ENGLEWOOD, Colo., March 6, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today updates the regulatory status of Ampion™. Food and Drug Administration (FDA) provided guidance that Ampio should complete an additional trial of Kellgren Lawrence Grade 4 (KL 4) osteoarthritis of the knee (OAK) patients with concurrent controls that would be carried out under a Special Protocol Assessment (SPA). Ampio presented the FDA with two different forms of concurrent controls the company was considering in trial design: a saline injection or a sham injection, both previously identified by the FDA as possible controls.
- GlobeNewswire
Research Report Identifies Wolverine World Wide, Viking Therapeutics, Ampio Pharmaceuticals, ArcelorMittal, Delphi Technologies, and Unit with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire
Ampio Updates Status of Pivotal Clinical Trial of Ampion to be Carried Out Under a SPA
ENGLEWOOD, Colo., Feb. 6, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it had received an initial response from the U.S. Food and Drug Administration (FDA), Office of Tissue and Advanced Therapies division regarding the Company's submission of a proposed trial design for the treatment of KL4 Osteoarthritis patients with Ampion™. Michael Macaluso, Ampio's CEO, explained: "A SPA is an agreement between the sponsor and FDA that the trial design, clinical endpoints, and statistical analyses could support marketing approval.
- PR Newswire
Ampio Updates Regulatory and Publication status for Ampion™
ENGLEWOOD, Colo., Nov. 26, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today updates the regulatory and peer-review publication status of Ampion. Statisticians representing Ampio and the FDA met recently to discuss the clinical pathway of Ampion™, the company's lead drug, for the treatment of severe Osteoarthritis-of-the-knee (OAK). All KL-4 patients, from each single injection trial, were subjected to a statistical review that resulted in the FDA scheduling an additional, internal meeting that will include reviewers from the Office of Tissue and Advanced Therapies (OTAT).
- ACCESSWIRE
3 Health Care Stocks Rallying After US Midterms
/ Healthcare stocks are rallying after Tuesday's US midterm elections. According to Modern Healthcare* the healthcare industry will continue to drive the nation's employment growth through 2026 by adding around 4 million new jobs, accounting for about a third of total job growth, according to Bureau of Labor Statistics data. Modern Healthcare cites that ''the healthcare industry has long fueled the country's economy.
- PR Newswire
Ampio Updates Regulatory and Clinical Status for Ampion™
ENGLEWOOD, Colo., Nov. 7, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today is providing an update of the regulatory and clinical path activities required to file a Biologics License Application (BLA) for Ampion™ for the treatment of severe osteoarthritis-of-the-knee (OAK). Ampio designed what it thought would be a final pivotal clinical trial of Ampion (AP-003-C), predominately under guidance from FDA CBER's Office of Blood Research and Review (OBRR).
- GlobeNewswire
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Ampio Pharmaceuticals, Inc. (AMPE) and Encourages AMPE Investors to Contact the Firm
NEW YORK, Oct. 30, 2018 -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Ampio Pharmaceuticals, Inc. (NYSE: AMPE)..
- ACCESSWIRE
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 24, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between December 14, 2017 and August 7, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before October 24, 2018.